Oligonucleotide Synthesis Market Worth $3.58 Billion, Globally, by 2027 at 10.45% CAGR: Verified Market Research

JERSEY CITY, New Jersey, June 8, 2020 /PRNewswire/ -- Verified Market Research recently published a report, "Oligonucleotide Synthesis Market By Product (Synthesized Oligonucleotides, Equipment, Reagents), By End Use (Pharmaceutical and Biotechnology Companies, Diagnostic Laboratories, Hospitals, Academic and Research Institutes), By Applications (Research, Diagnostics, Therapeutics)". According to the report, Global Oligonucleotide Synthesis Market was valued at USD 1.71 billion in 2019 and is projected to reach USD 3.58 billion by 2027, growing at a CAGR of 10.45% from 2020 to 2027.

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample/?rid=15651

Browse in-depth TOC on "Oligonucleotide Synthesis Market"
156 - Pages
31 – Tables
56 – Figures

Global Oligonucleotide Synthesis Market Overview

The increased prevalence of synthesized oligos used in molecular diagnostics and clinical applications is the factor for rise in market growth. Oligos are chemically synthesized, and are applied in many relevant areas of scientific research and development. These have become a point of focus in Molecular Biology and Biotechnology, due to the synthetic DNA and cell-made DNA having similar structural and chemical qualities. The antisense oligonucleotides are applied to reduce the stages of protein synthesis by suppressing Micro RNA translation. This method is foundation of many therapies which are undergoing clinical trials for a variety of cancer treatments. The role of favorable government initiatives for the funding, and increased Research and Development disbursements in Pharmaceutical and Biotechnology Companies are causing a surge in the market revenue. The U.S. government have informed the major companies to produce a set of best practices for customer and sequence screening prior to manufacture. Taken together, these protocols guarantee that synthetic DNA is used to advance research that is designed and intended for public benefit. Upcoming technological advancements in gene editing techniques are likely to become a game changer in oligo synthesis. Recent progress in designing programmed nucleases, such as zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and clustered regularly interspaced short palindromic repeat (CRISPR)–Cas-associated nucleases, has greatly accelerated the progress of gene editing from concept to clinical practice. The presence of a strong product range of oligonucleotide synthesis is also fueling the market growth. The oligonucleotides offer promising benefits for a wide range of medical assistances. In comparison with to small-molecular drugs as well as to large-molecule biopharmaceuticals, oligonucleotide pharmaceuticals are much more upfront to both design and develop. They allow for the development of therapeutics that affect protein targets that cannot be effectively treated by small-molecule or protein therapeutics. Other driving factors such as minimum sequencing cost, huge capital investments, public-private disbursements on Genomics are bound to increase the market revenue.

The restraints observed are the increased costs and investments in synthesized oligos. There is dearth of rules and regulations for safe use of synthesized oligos. The lack of increased wages of skilled employees and technicians, scarcity of skilled professional and expertise to handle the synthesized oligos. The challenges faced are the Antisense Oligonucleotide undergoing delayed supply chain. There are flaws in synthesis methods which sharply reduce the amount of available drug substance, analytical methods are not well developed. It is quite cumbersome to handle the oligos synthesized on a large scale, and the delivery of oligonucleotides to specific targets still remains a drawback. The major players in the market are Agilent Technologies, Inc. (US), ATDBio Ltd. (UK), Bio-Synthesis, Inc. (US), BioAutomation Corporation (US), LGC Biosearch Technologies (US), Biogen International (US), Sarepta Therapeutics (US), Eurofins Genomics (Germany), Eurogentec (Belgium), GeneDesign, Inc. (Japan), GE Healthcare (US), GenScript, Inc. (US), Integrated DNA Technologies (IDT, US), Nitto Denko Avecia, Inc. (US), Sarepta Therapeutics (US), Thermo Fisher Scientific, Inc. (US), TriLink BioTechnologies (US), and Sigma-Aldrich Corporation (US) (a part of Merck KGAA).

Verified Market Research has segmented the Oligonucleotide Synthesis Market On the Basis of Product, End Use, Application and Geography.

• Oligonucleotide Synthesis Market by Product
• Synthesized Oligonucleotides
• Equipment
• Reagents
• Oligonucleotide Synthesis Market by End Use
• Pharmaceutical and Biotechnology Companies
• Diagnostic Laboratories
• Hospitals
• Academic and Research Institutes
• Oligonucleotide Synthesis Market by Applications
• Research
• Diagnostics
• Therapeutics
• Oligonucleotide Synthesis Market by Geography
• North America
• U.S
• Canada
• Mexico
• Europe
• Germany
• France
• U.K
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Rest of Asia Pacific
• ROW
• Middle East & Africa
• Latin America

Browse Related Reports:

Genome Editing Market Size by Technology (TALEN, CRISPR, ZFN), by Application (Animal Genetic Engineering, Cell Line Engineering, Plant Genetic Engineering), by End-Use Industry (Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, Contract Research Organizations), by Geographic Scope And Forecast, 2020-2027

Next Generation Sequencing (NGS) Market by Application (Diagnostics, Biomarkers and Cancer, Reproductive Health, Personalized Medicine, Agriculture and Animal Research), by Product & Services (Sample Preparation Consumables, HiSeq, MiSeq, Ion Torrent, SOLiD, Pacbio Rs II and Sequel System), by Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Sequencing by Ligation, Pyrosequencing, Single Molecule Real Time Sequencing) and Forecast, 2020-2027

Synthetic Biology Market By Tool and Technology (Oligonucleotides, Enzymes, Cloning Technology Kits), By Application (Medical Applications, Industrial Applications, Food and Agriculture, Environmental Applications), by Geographic Scope And Forecast, 2020-2017

Non-Invasive Prenatal Testing (NIPT) Market by Application (Trisomy, Microdeletions Symptoms, Others), by Method (Biochemical Screening Test, Ultrasound Detection, Cell-Free DNA in Maternal Plasma Test), by Geographic Scope And Forecast, 2020-2027

About Us

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SME's offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defense, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & construction, Agriculture industry and Medical Devices from over 100 countries.

Contact Us
Mr. Edwyne Fernandes
Verified Market Research
US: +1-(650)-781-4080
UK: +44-(203)-411-9686
APAC: +91-(902)-863-5784
US Toll Free: +1-(800)-782-1768
Email: [email protected] 
Web: https://www.verifiedmarketresearch.com/ 
Follow Us: LinkedIn | Twitter

SOURCE Verified Market Research